DE69504949D1 - Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs - Google Patents

Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs

Info

Publication number: DE69504949D1
Authority: DE; Germany
Prior art keywords: antagonist; substance; treatment; skin redness; neurogenic origin
Prior art date: 1994-12-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69504949T

Other languages

English (en)

Other versions

DE69504949T2 (de

DE69504949T3 (de

Inventor

Lacharriere Olivier De

Lionel Breton

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

LOreal SA

Original Assignee

LOreal SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-19

Filing date

1995-11-17

Publication date

1998-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469930&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69504949(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-11-17 Application filed by LOreal SA filed Critical LOreal SA

1998-10-29 Application granted granted Critical

1998-10-29 Publication of DE69504949D1 publication Critical patent/DE69504949D1/de

1999-02-18 Publication of DE69504949T2 publication Critical patent/DE69504949T2/de

2004-01-15 Publication of DE69504949T3 publication Critical patent/DE69504949T3/de

2015-11-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 title 1
102100024304 Protachykinin-1 Human genes 0.000 title 1
101800003906 Substance P Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
230000001272 neurogenic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Birds (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE69504949T 1994-12-19 1995-11-17 Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs Expired - Lifetime DE69504949T3 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9415252A FR2728165A1 (fr)	1994-12-19	1994-12-19	Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene

Publications (3)

Publication Number	Publication Date
DE69504949D1 true DE69504949D1 (de)	1998-10-29
DE69504949T2 DE69504949T2 (de)	1999-02-18
DE69504949T3 DE69504949T3 (de)	2004-01-15

Family

ID=9469930

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69504949T Expired - Lifetime DE69504949T3 (de)	1994-12-19	1995-11-17	Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs

Country Status (15)

Country	Link
US (1)	US5744156A (de)
EP (1)	EP0722722B2 (de)
JP (1)	JPH08208508A (de)
AR (1)	AR000357A1 (de)
AT (1)	ATE171372T1 (de)
BR (1)	BR9505381A (de)
CA (1)	CA2165518C (de)
DE (1)	DE69504949T3 (de)
DK (1)	DK0722722T4 (de)
ES (1)	ES2124983T5 (de)
FR (1)	FR2728165A1 (de)
HU (1)	HU218944B (de)
MX (1)	MX9505192A (de)
PL (1)	PL311917A1 (de)
RU (1)	RU2140263C1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2732221B1 (fr) *	1995-03-28	1997-04-25	Oreal	Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2738742B1 (fr) *	1995-09-19	1997-11-14	Oreal	Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
DE69828615T2 (de) *	1997-10-31	2005-12-01	Walter Reed Army Institute Of Research	Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
US6958148B1 (en) *	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
FR2774285B1 (fr)	1998-02-03	2001-06-15	Roche Posay Lab Pharma	Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
US5972993A (en) *	1998-03-20	1999-10-26	Avon Products, Inc.	Composition and method for treating rosacea and sensitive skin with free radical scavengers
AR018376A1 (es) *	1998-05-26	2001-11-14	Novartis Ag	Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
DE10025553A1 (de) *	2000-05-24	2001-11-29	Merck Patent Gmbh	Zusammensetzung, enthaltend mindestens ein Aryloxim und mindestens einen Wirkstoff zur Behandlung von Akne und ihre Verwendung
WO2003037334A1 (en) *	2001-10-31	2003-05-08	Merck & Co., Inc.	Method for treating or preventing symptoms of hormonal variation including hot flashes
US20060263350A1 (en) *	2003-09-26	2006-11-23	Fairfield Clinical Trials Llc	Combination antihistamine medication
EP1600158A1 (de) *	2004-05-26	2005-11-30	Galderma Research & Development, S.N.C.	Verwendung von Ondansetron zur Behandlung von Entzündungen und Arzneimittel, die es enthalten
FR2866566A1 (fr) *	2004-02-20	2005-08-26	Galderma Res & Dev	Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
WO2007062060A2 (en)	2005-11-22	2007-05-31	Ted Reid	Methods and compositions using substance p to promote wound healing
WO2007137117A2 (en) *	2006-05-17	2007-11-29	Massachusetts Institute Of Technology	Aptamer-directed drug delivery
JP5204657B2 (ja)	2006-10-16	2013-06-05	ライオン株式会社	Ｎｋ１受容体アンタゴニスト組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5921656A (ja)	1982-07-28	1984-02-03	Takeda Chem Ind Ltd	ポリペプチド誘導体
US4472305A (en)	1983-05-17	1984-09-18	Sterling Drug Inc.	Hexapeptide amides
US4839465A (en)	1987-01-20	1989-06-13	Sterling Drug Inc.	Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
GB8807921D0 (en)	1988-04-05	1988-05-05	Fujisawa Pharmaceutical Co	Ws-9326 & its derivatives
US5187156A (en)	1988-03-16	1993-02-16	Fujisawa Pharmaceutical Co., Ltd.	Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
GB8807246D0 (en)	1988-03-25	1988-04-27	Merck Sharp & Dohme	Therapeutic agents
EP0360390A1 (de) †	1988-07-25	1990-03-28	Glaxo Group Limited	Spirolactamderivate
MX18467A (es)	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas
US5164372A (en)	1989-04-28	1992-11-17	Fujisawa Pharmaceutical Company, Ltd.	Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
FR2654726B1 (fr)	1989-11-23	1992-02-14	Rhone Poulenc Sante	Nouveaux derives de l'isoindolone et leur preparation.
FR2654725B1 (fr)	1989-11-23	1992-02-14	Rhone Poulenc Sante	Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB8929070D0 (en)	1989-12-22	1990-02-28	Fujisawa Pharmaceutical Co	Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
UA41251C2 (uk)	1990-01-04	2001-09-17	Пфайзер, Інк.	Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5232929A (en)	1990-11-28	1993-08-03	Pfizer Inc.	3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
EP0515681A4 (en)	1990-02-15	1993-12-29	Fujisawa Pharmaceutical Co., Ltd.	Peptide compound
EP0532515B1 (de)	1990-05-31	1996-10-23	Pfizer Inc.	Herstellung von substituierten piperidinen
CA2084193C (en)	1990-06-01	1998-04-07	John A. Lowe, Iii	3-amino-2-aryl quinuclidines
ATE129409T1 (de)	1990-12-21	1995-11-15	Fujisawa Pharmaceutical Co	Neue verwendung von peptidderivat.
EP0566589A1 (de)	1991-01-10	1993-10-27	Pfizer Inc.	N-alkyl chinuclidiniumsalze als substanz-p-antagoniste
ATE154354T1 (de)	1991-02-11	1997-06-15	Merck Sharp & Dohme	Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
US5373003A (en)	1991-03-01	1994-12-13	Pfizer Inc.	1-azabicyclo[3.2.2]nonan-3-amine derivatives
KR0145432B1 (ko)	1991-03-26	1998-07-15	알렌 제이. 스피겔	치환된 피페리딘의 입체선택적 제조 방법
FR2677361A1 (fr)	1991-06-04	1992-12-11	Adir	Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr)	1991-05-17	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux derives du thiopyranopyrrole et leur preparation.
FR2676446B1 (fr)	1991-05-17	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676442B1 (fr)	1991-05-17	1993-08-06	Rhone Poulenc Rorer Sa	Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676443B1 (fr)	1991-05-17	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux derives de perhydroisoindole et leur preparation.
EP0585328B1 (de)	1991-05-22	2002-01-09	Pfizer Inc.	Substituierte 3-aminochinuclidine
GB9113219D0 (en)	1991-06-19	1991-08-07	Fujisawa Pharmaceutical Co	Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
ES2092113T3 (es)	1991-06-20	1996-11-16	Pfizer	Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
TW202432B (de)	1991-06-21	1993-03-21	Pfizer
US5288730A (en) †	1991-06-24	1994-02-22	Merck Sharp & Dohme Limited	Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
US5472978A (en)	1991-07-05	1995-12-05	Merck Sharp & Dohme Ltd.	Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5629347A (en) †	1991-07-05	1997-05-13	Merck Sharp & Dohme Ltd.	Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5495047A (en) †	1991-07-10	1996-02-27	Merck, Sharp & Dohme (Ltd.)	Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en)	1991-08-12	1998-03-31	Ciba Geigy Ag	1-acylpiperindine compounds.
US5459270A (en)	1991-08-20	1995-10-17	Merck Sharp & Dohme Limited	Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
IL99368A (en) *	1991-09-02	1996-01-19	Teva Pharma	Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
JP2535134B2 (ja)	1991-09-16	1996-09-18	ファイザー・インコーポレーテッド	縮合三環式窒素含有複素環
JP2553020B2 (ja)	1991-11-07	1996-11-13	吉富製薬株式会社	キヌクリジン化合物およびその医薬用途
EP0545478A1 (de)	1991-12-03	1993-06-09	MERCK SHARP & DOHME LTD.	Heterocyclische Verbindungen als Tachykininantagoniste
GB9201179D0 (en) †	1992-01-21	1992-03-11	Glaxo Group Ltd	Chemical compounds
JPH05339240A (ja) *	1992-06-04	1993-12-21	Yamanouchi Pharmaceut Co Ltd	テトラヒドロイソキノリンアミド誘導体
IL106142A (en) *	1992-06-29	1997-03-18	Merck & Co Inc	Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
GB9222486D0 (en) †	1992-10-26	1992-12-09	Merck Sharp & Dohme	Therapeutic agents
FR2719474B1 (fr) †	1994-05-05	1996-05-31	Oreal	Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.

1994
- 1994-12-19 FR FR9415252A patent/FR2728165A1/fr active Granted
1995
- 1995-11-17 AT AT95402582T patent/ATE171372T1/de not_active IP Right Cessation
- 1995-11-17 EP EP95402582A patent/EP0722722B2/de not_active Expired - Lifetime
- 1995-11-17 ES ES95402582T patent/ES2124983T5/es not_active Expired - Lifetime
- 1995-11-17 DE DE69504949T patent/DE69504949T3/de not_active Expired - Lifetime
- 1995-11-17 DK DK95402582T patent/DK0722722T4/da active
- 1995-12-08 BR BR9505381A patent/BR9505381A/pt active Search and Examination
- 1995-12-11 MX MX9505192A patent/MX9505192A/es unknown
- 1995-12-15 AR AR33463595A patent/AR000357A1/es not_active Application Discontinuation
- 1995-12-18 RU RU95121082A patent/RU2140263C1/ru active
- 1995-12-18 CA CA002165518A patent/CA2165518C/fr not_active Expired - Lifetime
- 1995-12-18 PL PL95311917A patent/PL311917A1/xx unknown
- 1995-12-18 JP JP7329300A patent/JPH08208508A/ja active Pending
- 1995-12-18 HU HU9503625A patent/HU218944B/hu not_active IP Right Cessation
- 1995-12-19 US US08/574,856 patent/US5744156A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK0722722T3 (da)	1999-06-14
ATE171372T1 (de)	1998-10-15
DE69504949T2 (de)	1999-02-18
BR9505381A (pt)	1997-11-18
CA2165518C (fr)	2002-07-16
FR2728165A1 (fr)	1996-06-21
EP0722722A1 (de)	1996-07-24
PL311917A1 (en)	1996-06-24
HU218944B (hu)	2001-01-29
DE69504949T3 (de)	2004-01-15
HU9503625D0 (en)	1996-02-28
US5744156A (en)	1998-04-28
EP0722722B2 (de)	2003-03-05
HUT74948A (en)	1997-03-28
ES2124983T5 (es)	2003-11-16
AR000357A1 (es)	1997-06-18
MX9505192A (es)	1997-04-30
JPH08208508A (ja)	1996-08-13
FR2728165B1 (de)	1997-02-07
RU2140263C1 (ru)	1999-10-27
ES2124983T3 (es)	1999-02-16
DK0722722T4 (da)	2003-07-07
CA2165518A1 (fr)	1996-06-20
EP0722722B1 (de)	1998-09-23

Legal Events

Date	Code	Title	Description
1999-09-09	8363	Opposition against the patent
2003-05-08	8366	Restricted maintained after opposition proceedings

Publication	Publication Date	Title
ATE214274T1 (de)	2002-03-15	Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE4391418T1 (de)	1994-05-05	Vorrichtung zur elektrochemischen Behandlung von Wasser
DE69724016D1 (de)	2003-09-11	Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE59611411D1 (de)	2007-02-22	Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69504949D1 (de)	1998-10-29	Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs
DE69941566D1 (de)	2009-12-03	N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE179610T1 (de)	1999-05-15	Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69307509D1 (de)	1997-02-27	Vorrichtung zur behandlung von herzfehlern
ATE527022T1 (de)	2011-10-15	Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69827126D1 (de)	2004-11-25	Verwendung von hypothalamus-hemmfaktor zur behandlung von ischämischen herzstörungen
ATE173620T1 (de)	1998-12-15	Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69405919T2 (de)	1998-03-05	Zusammensetzungen zur Behandlung von Keratinfasern
ATE218862T1 (de)	2002-06-15	Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69939723D1 (de)	2008-11-20	Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE50011325D1 (de)	2006-02-23	Vorrichtung zur Erkennung der Kreislaufwirkungen von Extrasystolen
DE69931487D1 (de)	2006-06-29	Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69729735D1 (de)	2004-08-05	Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69706758T2 (de)	2002-07-04	Verfahren zur Behandlung von Polyolefin
DE69924284D1 (de)	2005-04-21	Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69404725D1 (de)	1997-09-11	Verfahren zur elektrolytischen Behandlung von Altbatterien
DE69408394T2 (de)	1998-06-18	4-Piperidino-piperidin zur Behandlung von Tumoren
DE69430545T2 (de)	2002-11-07	Verwendung von penciclovir zur behandlung von postherpetischer neuralgie
DE69926996D1 (de)	2005-10-06	Verwendung von riluzol zur behandlung der retinalischemie
DE59904564D1 (de)	2003-04-17	Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
DE69519219T2 (de)	2001-02-22	Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie